Barclays analyst Matt Miksic raised the firm’s price target on Johnson & Johnson to $175 from $171 and keeps an Equal Weight rating on the shares. The firm raised its sales and EPS estimates to reflect the company’s Q2 beat and increased growth outlook. The firm also delayed the projected decline in Stelara from 2024 to 2025, based on the IP settlements announced by the company.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on JNJ:
- Wall Street Goes the Irrational Route with Kenvue Stock (NYSE:KVUE)
- Johnson & Johnson Launches Exchange Offer Regarding Separation of Kenvue
- Kenvue to file S-4 registration statement in connection with JNJ exchange offer
- Johnson & Johnson launches exchange offer for separation of Kenvue
- Stock Gains as JNJ Goes on Legal Offensive
